May 14, 2020 / 12:28 PM / 12 days ago

BRIEF-Advaxis Announces Updated Positive Clinical And Biomarker Data From Ongoing Phase 1/2 Adxs-503 Trial In NSCLC

May 14 (Reuters) - Advaxis Inc:

* ADVAXIS ANNOUNCES UPDATED POSITIVE CLINICAL AND BIOMARKER DATA FROM ONGOING PHASE 1/2 ADXS-503 TRIAL IN NSCLC

* ADVAXIS INC - POSITIVE PRELIMINARY IMMUNOGENICITY DATA WITH CD8+ T CELLS GENERATED IN ALL OF FIRST SEVEN PATIENTS EVALUATED FOR ADXS-503 ANTIGENS

* ADVAXIS INC - SUSTAINED CLINICAL BENEFIT SEEN IN PATIENTS TREATED WITH ADXS-503 IN COMBINATION WITH KEYTRUDA® AFTER 16 WEEKS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below